Munapsys™ is a next-generation biomimetic peptide, developed using in silico molecular design techniques with the aim of reproducing a relaxing effect on facial muscles in a cosmetic and topical form.
Its INCI name is Acetyl Hexapeptide-1, and it stands out in the field of neurocosmetics for a mechanism of action that involves both nerve transmission (the pre-synaptic phase) and the muscular response (the post-synaptic phase).
[INDICE:h2]
What Is Munapsys™? Origin and Design
Munapsys™ was designed using an approach known as in silico design, which uses computational algorithms to simulate interactions between molecules and target proteins. The peptide was optimized to compete with the Munc-18 protein, a key component of the SNARE complex, interfering with the release of acetylcholine, which is responsible for muscle contraction.
It consists of 99.4% naturally derived ingredients according to the ISO 16128 standard, comes as a highly soluble aqueous solution, and is used at concentrations ranging from 2% to 5%.
How It Works
Pre-synaptic action: acetylcholine release
In the neuromuscular system, contraction is activated by the release of acetylcholine (ACh) from the motor neuron’s synaptic vesicles. This release depends on the correct assembly of the SNARE protein complex, made up of Munc-18, syntaxin, SNAP-25, and VAMP.
Munapsys™ is designed to interfere with the Munc-18 protein, reducing its ability to bind to syntaxin and thereby hindering the formation of the SNARE complex. The result is reduced acetylcholine release, with an attenuated, temporary, and reversible effect.
Post-synaptic action: the muscular response
The second characteristic of Munapsys™ concerns the muscle. Unlike Argireline® (Acetyl Hexapeptide-8), which acts only at the level of the nerve signal, this peptide also modulates the expression of genes involved in muscle contraction.
In experimental models using human myocytes, the manufacturer reports a reduction in intracellular calcium mobilization, myosin levels, and the expression of certain contractile genes (ATP2A, TNNC1, MYH1, ACTA1, CACNB1, SCN3A).
This dual level of action — pre- and post-synaptic — is what distinguishes Munapsys™ from other muscle-relaxing peptides on the market.
Data Reported by the Manufacturer
The testing portfolio includes in vitro tests on neuronal and muscle cell models, ex vivo tests on neuron-myofiber co-cultures, and in vivo tests on a group of female volunteers between the ages of 35 and 55.
The in vitro tests report a reduction in Munc-18/syntaxin interaction, a decrease in exocytosis in neurons, and lower myosin levels in treated myocytes.
For the clinical test, conducted over 14 days on 18 female volunteers using a 3% cream and assessed with PRIMOS and VISIA instruments, the manufacturer reports a reduction in roughness and the depth of expression lines, with results observable as early as the first week.
As with all patented cosmetic active ingredients, these data come from tests conducted by the ingredient manufacturer and not from independent clinical studies published in peer-reviewed journals. The in vivo test sample was also small (18 subjects) and the duration short: these findings indicate potential efficacy in a formulation, but are not definitive proof. The mechanism of action involving the SNARE complex is, however, described in the scientific literature.
Which Wrinkles Does It Target?
Munapsys™ delivers the best results on dynamic wrinkles, which are caused by repeated movement of the facial muscles:
- glabellar lines, between the eyebrows;
- forehead lines;
- crow’s feet;
- perioral lines.
Its effect is more limited on static wrinkles that are already established in the dermis due to the loss of collagen and elastin. In that case, active ingredients that work on the dermal matrix are needed, such as signal peptides or collagen stimulators.
Safety and Tolerability
According to the safety data provided by the manufacturer, Munapsys™ has shown no skin or eye irritation in in vitro tests on reconstructed epidermis, no sensitizing potential in the HRIPT, and good stability in formulations. It can therefore also be used on sensitive skin.
Munapsys™ in LeLang’s Multi Peptide Lift
We chose this peptide for Multi Peptide Lift — Botoxil Technology, the intensive face serum designed to smooth expression lines without resorting to invasive treatments.
Multi Peptide Lift Formula - Botoxil Technology Anti-wrinkle face serum with Botoxil Technology™ Two biomimetic peptides for expression lines, biotechnological resve... Discover Multi Peptide Lift Formula - Botoxil Technology
Use it as a daily serum before your face cream. It is suitable from the age of 30 onward for those with pronounced expression lines or anyone who prefers a non-invasive approach.
As with all peptides, its effect depends on consistent use: when application is discontinued, the muscles gradually return to their usual behavior.
An important clarification. Functional cosmetics do not replace aesthetic medicine. A topical peptide acts on the surface, with much lower intensity and in a reversible manner compared with an injectable treatment, which is a medical procedure. Munapsys™ is a valuable at-home routine, potentially used alongside aesthetic medicine, or an alternative for those seeking non-invasive solutions — but it is not the same thing and should not be presented as such.
On the Acetyl Hexapeptide-1 ingredient page, you can find the complete list of LeLang formulas that contain it.
You can also find LeLang products in partner pharmacies throughout Italy.
Frequently Asked Questions
What is the difference between Munapsys™ and Argireline®?
Both act on the transmission of the signal that triggers contraction, but they target different components: Argireline® interferes with SNAP-25, while Munapsys™ acts on Munc-18 and also works downstream, affecting the muscle cell’s response.
How long does it take to see results?
The manufacturer’s tests report instrumentally measurable changes within two weeks. For a noticeable improvement visible to the naked eye, consistent use for several weeks is required.
Is it suitable for sensitive skin?
Yes, tolerability tests showed no irritating or sensitizing potential. During pregnancy and breastfeeding, as with all cosmetic active ingredients, it is advisable to consult your doctor.
Free 15-Minute Consultation with the Founder
Would you like to find out whether a peptide treatment is suitable for your expression lines? Book a free virtual skincare consultation with Elisa Avalle, founder of LeLang.
